Biomedical subjects

Beatrix Cochand-Priollet

Publications and source records attributed to Beatrix Cochand-Priollet.

3 recordsLinked to original sources

PubMed2006

Discriminating benign from malignant thyroid lesions using artificial intelligence and statistical selection of morphometric features.

The objective of this study was to perform a comparative investigation of the capability of various classifiers in discriminating benign from malignant thyroid lesions. Using May Grunvald-Giemsa-stained smears taken by fine needle aspiration (FNA) and a custom image analysis system, 25 nuclear features describing the size, shape and texture of the nuclei were measured in each case. A statistical pre-processing of features revealed that only 4 of the 25 features are important when discriminating benign from malignant thyroid lesions, which were transformed and fed to four classifiers for subsequent analysis. The cases were divided into one set used for the training of classifiers, a second set used as the test set, and the remaining cases with no clear classification formed an ambiguous test set. Classification was performed at the nuclear and patient level. The technique described in this study produced encouraging results and promises to be a helpful tool in the daily cytological laboratory routine.

Anthropometry↗

PubMed2002

Cost of screening for cancerous and precancerous lesions of the cervix.

This paper is part of the cost-effectiveness study of cervical cancer screening conducted by the French Society of Clinical Cytology (SFCC). It describes the evaluation of costs of conventional smear tests, thin-layer smear tests (ThinPrep 2000 system), and viral typing by the HCS test. For 100,000 examinations per year, the average cost of a conventional smear test is 11.53 dollars in a private anatomo-pathology clinic. The cost of the thin-layer test for the same number of examinations and in the same type of clinic is 13.93 dollars. For 20,000 annual tests, the average cost of human papillomavirus (HPV) is 23.43 dollars in the public sector and 23.48 dollars in the private one. The higher price of the thin-layer method is only justifiable if this screening technique outperforms the conventional method. Furthermore, the high cost of the HPV test means that its integration into a population-based screening program must be carefully defined.

Cost-Benefit Analysis↗

PubMed2002

Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate.

OBJECTIVE: Benign prostatic hyperplasia (BPH) is the most common benign tumour in ageing men. While the etiopathology remains unsolved, a disruption in the endocrine/autocrine-paracrine prostatic homeostasis, involving steroid hormones, contributes to the pathogenesis of BPH. DNA polymorphisms in genes involved in hormone synthesis, signalling and metabolism may, therefore, be responsible for these changes. We have evaluated the correlation between specific genotypes in androgen- and oestrogen-regulating genes (AR, SRD5A2, CYP17 and CYP19), and age-related prostatic changes. METHODS: We have tested genetic susceptibility to morphological and pathological criteria in 195 French Caucasians, using allelic variants for candidate genes involved in androgen/oestrogen prostatic activity: androgen receptor (CAG repeats), 5alpha-reductase type 2 (TA repeats, V89L and A49T mutations), A2 variant of the 17alpha-hydroxylase (CYP17) and the simple tandem repeat polymorphism (STRP) aromatase (CYP19) polymorphisms. RESULTS: The A2 variant of 17alpha-hydroxylase (CYP17) and allele 191 of STRP aromatase (CYP19) showed an opposite effect on age-related prostate hyperplasia: CYP17 being associated with increased risk of prostate enlargement and CYP19 with reduced risk. The 5alpha-reductase type II variants studied did not show links with prostate hyperplasia. The androgen receptor gene CAG repeat length showed a low correlation with the increase of prostate weight, suggesting some effect on age-related prostate growth. CONCLUSION: These results suggested that common variants of the CYP17 gene are associated with prostate enlargement and therefore may increase the risk of development of BPH in this population, while infrequent variants of the aromatase gene (CYP19) could be of a protective nature.

Androgens↗